Dr. Beuming leads the In Silico Drug Discovery Services at LBG. He has more than 15 years of experience applying computational biophysics, computational chemistry, bioinformatics, and cheminformatics to problems in biology and drug discovery in academia and industry.
Prior to joining LBG, Dr. Beuming spent more than a decade at Schrödinger, Inc., the global leader in providing computational chemistry and molecular modeling solutions to the biopharmaceutical and materials industries. He held a leading role in the Application Science department at Schrödinger, where he managed project and customer support for clients in the New York, New Jersey, and Pennsylvania regions.
Dr. Beuming has supervised technology implementations in a variety of fields, including ligand- and structure-based small molecule discovery and biologics research. He also made extensive contributions to Schrödinger’s in-house drug discovery projects while serving in the role of Research Leader in the Drug Discovery Applications Group.
In addition, Dr. Beuming has made key contributions to novel methodologies of key problems in computational chemistry, including the study of protein flexibility, protein solvation, thermodynamic binding affinity calculations, and small molecule and peptide docking. His work has been documented in more than 50 peer-reviewed articles and reviews.
Dr. Beuming holds an M.S. in Medicinal Chemistry from the Vrije Universiteit in Amsterdam, Netherlands, and a Ph.D. in Physiology and Biophysics from Weill Medical College at Cornell University, where he focused on elucidating structure function studies of neurotransmitter transporters.